Spravato Information
- Home
- Spravato Information
Spravato® (Esketamine)
What Is Spravato®?
Spravato® (esketamine) is an FDA-approved nasal spray used to treat adults with:
• Treatment-resistant depression (TRD)
• Major depressive disorder (MDD) with suicidal thoughts or behaviors
Spravato® works differently from traditional antidepressants by targeting the brain’s glutamate system, which may lead to faster symptom relief for some patients.
Spravato®
How Is Spravato® Given?
- Administered as a nasal spray in a certified medical office
- Self-administered under direct supervision of a healthcare provider
- Cannot be taken at home
- Patients are monitored in the clinic for at least 2 hours after each dose
- Used together with an oral antidepressant

Spravato®
Typical Treatment Schedule
Weeks 1–4
Twice weekly
Weeks 5–8
Once weekly
Maintenance
Every 1–2 weeks as determined by your provider
Spravato®
Who Should Not Receive Spravato®
Use with caution if you have a history of psychosis, substance use disorder, liver disease, or are pregnant or breastfeeding.
Spravato® is not appropriate for patients with:
History of brain bleeding or aneurysms
Uncontrolled high blood pressure
Uncontrolled high blood pressure
Allergy to esketamine or ketamine
Important Patient Requirements
Must be 18 years or older
Must arrange transportation home
Must remain in the clinic for observation after treatment
Must not drive or operate machinery on treatment days
Do not eat for 2 hours or drink liquids for 30 minutes before treatment
Participation in the FDA-required REMS program is mandatory
Questions?
Please contact Farratti Psychiatry if you have questions or would like to know if Spravato® may be right for you.